Cargando…
Antiviral neutralizing antibodies: from in vitro to in vivo activity
Neutralizing antibodies (nAbs) are being increasingly used as passive antiviral reagents in prophylactic and therapeutic modalities and to guide viral vaccine design. In vivo, nAbs can mediate antiviral functions through several mechanisms, including neutralization, which is defined by in vitro assa...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108814/ https://www.ncbi.nlm.nih.gov/pubmed/37069260 http://dx.doi.org/10.1038/s41577-023-00858-w |
_version_ | 1785026920529788928 |
---|---|
author | Burton, Dennis R. |
author_facet | Burton, Dennis R. |
author_sort | Burton, Dennis R. |
collection | PubMed |
description | Neutralizing antibodies (nAbs) are being increasingly used as passive antiviral reagents in prophylactic and therapeutic modalities and to guide viral vaccine design. In vivo, nAbs can mediate antiviral functions through several mechanisms, including neutralization, which is defined by in vitro assays in which nAbs block viral entry to target cells, and antibody effector functions, which are defined by in vitro assays that evaluate nAbs against viruses and infected cells in the presence of effector systems. Interpreting in vivo results in terms of these in vitro assays is challenging but important in choosing optimal passive antibody and vaccine strategies. Here, I review findings from many different viruses and conclude that, although some generalizations are possible, deciphering the relative contributions of different antiviral mechanisms to the in vivo efficacy of antibodies currently requires consideration of individual antibody–virus interactions. |
format | Online Article Text |
id | pubmed-10108814 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-101088142023-04-18 Antiviral neutralizing antibodies: from in vitro to in vivo activity Burton, Dennis R. Nat Rev Immunol Review Article Neutralizing antibodies (nAbs) are being increasingly used as passive antiviral reagents in prophylactic and therapeutic modalities and to guide viral vaccine design. In vivo, nAbs can mediate antiviral functions through several mechanisms, including neutralization, which is defined by in vitro assays in which nAbs block viral entry to target cells, and antibody effector functions, which are defined by in vitro assays that evaluate nAbs against viruses and infected cells in the presence of effector systems. Interpreting in vivo results in terms of these in vitro assays is challenging but important in choosing optimal passive antibody and vaccine strategies. Here, I review findings from many different viruses and conclude that, although some generalizations are possible, deciphering the relative contributions of different antiviral mechanisms to the in vivo efficacy of antibodies currently requires consideration of individual antibody–virus interactions. Nature Publishing Group UK 2023-04-17 /pmc/articles/PMC10108814/ /pubmed/37069260 http://dx.doi.org/10.1038/s41577-023-00858-w Text en © Springer Nature Limited 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Article Burton, Dennis R. Antiviral neutralizing antibodies: from in vitro to in vivo activity |
title | Antiviral neutralizing antibodies: from in vitro to in vivo activity |
title_full | Antiviral neutralizing antibodies: from in vitro to in vivo activity |
title_fullStr | Antiviral neutralizing antibodies: from in vitro to in vivo activity |
title_full_unstemmed | Antiviral neutralizing antibodies: from in vitro to in vivo activity |
title_short | Antiviral neutralizing antibodies: from in vitro to in vivo activity |
title_sort | antiviral neutralizing antibodies: from in vitro to in vivo activity |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108814/ https://www.ncbi.nlm.nih.gov/pubmed/37069260 http://dx.doi.org/10.1038/s41577-023-00858-w |
work_keys_str_mv | AT burtondennisr antiviralneutralizingantibodiesfrominvitrotoinvivoactivity |